Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis (NMDARE-HSE)

Civil Hospices of Lyon

Status: Unknown

Conditions: Anti NMDA Receptor Encephalitis; Herpetic Encephalitis; Autoimmune Encephalitis

Treatments: Other: Description and analysis

Study type: Observational

Funder types: Other

Identifiers

NCT04339127

NMDARE-HSE

Details and patient eligibility

About

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.

One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.

The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Enrollment: 12 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF
• After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
• Without age limit

Exclusion Criteria- No respect of inclusion criteria

Trial design

12 participants in 1 patient group

Cohort NMDARE-HSE

Description:

Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.

Treatment:

Other: Description and analysis